Business
In this episode of Denatured, you’ll be listening to Jane Hughes, President of R&D and Co-founder of Verdiva Bio, and Jon Rees, CEO and Co-founder of MitoRx Therapeutics. We’ll discuss next-generation obesity solutions tackling GLP-1’s muscle loss and adherence challenges, through innovative muscle preservation, oral administration and combination therapy.
FEATURED STORIES
An analysis finds that pharmas frequently file multiple similar patents on drugs, then use them as the basis for questionable litigation against would-be competitors.
The limited supply of this common reagent is set to drive drug prices higher, but there are ways for companies to lessen the impact.
Suppliers are investing in production to support deals with AstraZeneca, Bayer and other drugmakers that are advancing radioisotope-based cancer therapies.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The collaboration between Spark and NeuExcell increased the hope for Huntington’s disease cure in near future. This is going to be a great relief for all the patients.
Exelixis is mourning the loss of two veteran executives—Dr. Gisela M. Schwab, president, Product Development and Medical Affairs and CMO, and Jon Berndt, senior VP of Sales.
Adaptimmune will be responsible for developing clinical T-cell candidates for the two companies through its induced pluripotent stem cell (iPSC) derived allogeneic platform.
Scopus Biopharma recently launched Duet Therapeutics to integrate its immunotherapy assets’ management and clinical development with Olimmune.
With the adaptation of new technologies, tech executives are finding new homes in biotech and the life sciences.
Lilly’s most recent legal woes come from a proposed class-action lawsuit filed on Wednesday, accusing the company of age bias.
The life sciences industry was well-represented, with a handful of names featured in the top 100.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
BioLabs is opening its next hub in Dallas in a 37,000-square-foot flexible life science facility. The Biotech+ Hub can accommodate 35 startups, for which it’s now accepting applications.
Between April 2020 and today, the executive board of Kyowa Kiran North America (KKNA) has grown from being predominantly male to a 50/50 gender split.